Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in mild or asymptomatic COVID-19
NCT04346628Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Placebo (2 arms). Primary endpoint: Time Until Cessation of Oral Shedding of SARS-CoV-2 Virus up to 28 days. Started Jul 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04346628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346628.